Quality by Design - Course about modern pharmaceutical development

Quality by design (QbD) in pharmaceutical development 

Quality by Design lies at the very heart of modern pharmaceutical development. The implementation of QbD principles provides a cost-effective approach to delivering high quality medicines to patients. Regulatory authorities, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), are placing increasing importance on the QbD component as a part of regulatory filing. As such, QbD has become a crucial element in a streamlined drug development process.

This course will provide you with insight into the key principles of QbD including quality risk management, formal experimental design and process analytical technology (PAT). Leading QbD experts from industry, from the regulatory side and from the academic world will acquaint you with the current knowledge on QbD and offer ideas about how this knowledge can be applied in your company. The course includes practical demonstrations.

The course will introduce the underlying principles and tools required for QbD-based pharmaceutical development and manufacturing:

  • Basic risk analysis techniques
  • Constructing the Quality Target Product Profile (QTPP)
  • Identification of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)
  • Design of Experiments (DoE): Basic screening designs and expanded designs
  • Process Analytical Technologies (PAT): Basic principles of multivariate data analysis (chemometrics), looking at examples of process measurements applied to both small molecules and biopharmaceuticals, and for batch and continuously operating processes
  • Risk-based regulatory framework

The course is intended as Continuing Professional Development (CPD) for professionals in the pharmaceutical industry, particularly in production, regulatory affairs and quality functions. The course serves as an excellent introduction for those less familiar with QbD, while participants who have more experience with QbD will gain new insight into how to further implement the company’s QbD programme.

The course is preapproved as an elective in the Master of Industrial Drug Development (MIND) programme and the Master of Medicines Regulatory Affairs (MRA) programme. It has been developed in co-operation with the Steering Committee of the EUFEPS QbD and PAT Sciences Network (EUFEPS, European Federation for Pharmaceutical Sciences).

Participants must:

  • Hold a relevant bachelor degree or equivalent
  • Have a minimum of 2 years of relevant job experience
  • Be proficient at English

 

Share this page

Testimonials

“Very inspiring and relevant for my daily work and upcoming challenges in both development and commercial manufacturing”
Steffen Uebel, Manager Quality Assurance, STADA Arzneimittel AG

“Very educational. Teachers are very passionate and knowledgeable.“
Wendy van Loon, Quality Assessor, Medicines Evaluation Board, Utrecht

“I enjoyed speakers with different backgrounds.”
Lukas Taujenis, Scientist, Thermofisher Scientific, Vilnius

"The course was very well organised and gave an excellent mix of activities throughout each day. All guest lecturers were excellent."
Susan Fetherston, Development Engineer, QPharma AB.

Course directors

Course information

Duration: 5 days
Dates and time: August 19-23, 2019, 9 am - 4.30 pm
Price: EUR 2,680 (DKK 19,900) excl. Danish VAT. The price includes tuition, course material and all meals during course hours.
Language: English
Location: South Campus, Faculty of Law, Njalsgade 76, DK-2300 Copenhagen S, Denmark
Registration deadline: May 31, 2019
Contact: Copenhagen Summer University
csu@adm.ku.dk
+45 3533 3423


Download PDF